GlassScriptPhysician profile
Jianhua Wang
NPI 1053406421
$5,491.63
in general payments reported to CMS, 2019-2025
35 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $67.70 · 2022: $647 · 2023: $973 · 2024: $1,637 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,536.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $975.46 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $889.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $765.24 | 2022-2025 | Qulipta, Ubrelvy, Viberzi |
| Novo Nordisk INC | $582.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $343.82 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $263.46 | 2019-2025 | |
| Amgen INC. | $247.36 | 2019-2025 | Uplizna, Repatha, Repatha |
| Exact Sciences Corporation | $233.53 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $217.74 | 2019-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $182.58 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.99 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $74.99 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $71.05 | 2020-2025 | Trintellix |
| Amarin Pharma, INC. | $59.68 | 2019 | |
| Xeris Pharmaceuticals, INC. | $47.10 | 2024 | Keveyis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.89 | 2023-2025 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.28 | 2019-2022 | |
| Dynavax Technologies Corporation | $33.19 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $31.94 | 2019-2023 | |
| Dexcom, INC. | $31.84 | 2022-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $30.68 | 2022 | |
| Inspire Medical Systems, INC. | $28.31 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $24.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.37 | 2024 | Unithroid |
| Ibsa Pharma INC. | $18.75 | 2022 | |
| Esperion Therapeutics, INC. | $16.67 | 2020 | |
| Shire North American Group INC | $16.39 | 2019 | |
| Lundbeck LLC | $15.68 | 2025 | Rexulti |
| Nabriva Therapeutics, Plc | $15.23 | 2020 | |
| Currax Pharmaceuticals LLC | $15.02 | 2024 | Contrave |
| Supernus Pharmaceuticals, INC. | $14.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.99 | 2022 | |
| Sanofi Pasteur INC. | $12.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.72 | 2022 | |
| Genentech USA, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianhua Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.